Review of select transplant subpopulations at high risk of failure from standard immunosuppressive therapy

Clinical Transplantation

Volumn 14, Issue 5, 2000, Pages 439-448

  Deierhoi, Mark H ^a   Iii, Marcus Haug ^b  

^a Kentucky   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cyclosporine; Graft rejection; Immunosuppression; Pharmacokinetics; Tacrolimus; Transplantation

Indexed keywords

ANTILIPEMIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; ESTROGEN; GEMFIBROZIL; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PRAVASTATIN; PREDNISONE; PROGESTERONE; TACROLIMUS;

ADULT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; GRAFT REJECTION; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MICROEMULSION; NEGRO; ORGAN TRANSPLANTATION; PATIENT MONITORING; PEDIATRICS; POPULATION RESEARCH; PREGNANCY; PRIORITY JOURNAL; RECIPIENT; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AFRICAN AMERICANS; CHILD; CYSTIC FIBROSIS; DIABETES MELLITUS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MALE; PREGNANCY; RISK FACTORS; TREATMENT FAILURE;

EID: 0033814681     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.2000.140501.x     Document Type: Review

References (75)

1. 15 years of pediatric heart transplantation at the University of Pittsburgh: Lessons learned and future prospects
2. Growth after renal transplantation: Correlation with immunosuppressive therapy
3. Improved cadaveric renal transplant outcome in children
4. Diabetes mellitus after renal transplantation in the cyclosporine era - An analysis of risk factors
5. Post-transplant diabetes mellitus and methylprednisone pharmacokinetics in African-American and Caucasian renal transplant recipients
6. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation
7. Cyclosporine bioavailibility: Dosing implications and impact on clinical outcomes in select transplantation subpopulations
8. Children are different: The challenges of pediatric renal transplantation
9. Steady improvement in renal allograft survival among North American children: A five year appraisal by the North American pediatric renal transplant cooperative study
10. Effect of recipient's race on pediatric renal allograft survival: A single-center study
11. Renal transplantation in children from 1987-1996: The 1996 annual report of the North American pediatric renal transplant cooperative study
12. Risk factors for chronic rejection in pediatric renal allograft recipients
13. Cyclosporin pharmacokinetics in paediatric transplant recipients
14. Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients
15. Pharmacokinetics of cyclosporine after renal transplant in children
16. Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations
17. Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients
18. Experience with FK506 in living-related liver transplantation
19. Comparison of pharmacokinetics between CsA capsules and Sandimmun Neoral in pediatric patients
20. Pharmacokinetics of an oral solution of the microemulsion formulation of cyclosporine in maintenance pediatric liver transplant recipients
21. Use of Neoral in pediatric renal transplantation
22. Absorption characteristics of a microemulsion formulation of cyclosporine in de novo pediatric liver transplant recipients
23. Conversion from cyclosporine to Neoral in pediatric recipients for kidney, liver, and heart transplantation
24. Cadaver renal transplantation in children: Results with long-term cyclosporine immunosuppression
25. The pediatric nephrologist's dilemma: Growth after renal transplantation and its interaction with age as a possible immunologic variable
26. Steroid withdrawal after pediatric liver transplantation
27. Pediatric renal transplantation under tacrolimus-based immunosuppression
28. Growth following renal transplantation in children
29. Comparison of FK-506 and cyclosporine regimens in pediatric renal transplantation
30. Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506)
31. New-onset diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression
32. Kidney graft survival rates in black cyclosporine-treated recipients
33. Causes of renal allograft loss in black vs. white transplant recipients in the cyclosporine era
34. New immunosuppression strategies are needed to improve kidney allograft survival in blacks
35. Inferior outcome of two-haplotype matched renal transplants in blacks: Role of early rejection
36. Improved survival of primary cadaveric renal allografts in blacks with quadruple immunosuppression
37. OKT3 induction therapy and cadaveric renal transplantation in black patients
38. Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients
39. Single center analysis of mycophenolate mofetil and Neoral/prednisone therapy for prophylaxis of rejection in African-American and Caucasian transplant recipients
40. Immunosuppressive therapy in high-risk transplant patients: Dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients
41. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability
42. The adverse impact of high cyclosporine: Clearance rates on the incidences of acute rejection and graft loss
43. Cyclosporine pharmacokinetics and variability from a microemulsion formulation - A multicenter investigation in kidney transplant patients
44. Ethnic differences in tacrolimus pharmacokinetics in renal transplant candidates
45. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine
46. Racial variation in dosage requirements of tacrolimus
47. A case control study of renal transplantation in patients with type I diabetes
48. Trends in kidney transplantation in the United States
49. Predictors of long-term primary cadaveric renal transplant survival
50. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: A southeastern organ procurement foundation multicenter clinical study
51. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation
52. The effects of pravastatin on hyperlipidemia in renal transplant recipients
53. Treatment of hyperlipidemia in renal transplant patients with gemfibrozil and dietary modification
54. Reversal of cyclosporine malabsorption in diabetic recipients of simultaneous pancreas and kidney transplants using a microemulsion formulation
55. Importance of cyclosporine dosage and blood levels in simultaneous pancreas and kidney transplant success
56. Cyclosporine in multi-drug therapy in living-related kidney transplantation
57. Tacrolimus dosing requirements in diabetic and nondiabetic patients calculated from pretransplantation data
58. Cyclosporine pharmacokinetics in renal allograft recipients with diabetes mellitus treated with Sandimmune and Sandimmune Neoral
59. Cyclosporine resorption in diabetic patients after simultaneous pancreas and kidney transplantation
60. Commentary on a comparison of tacrolimus and cyclosporine for immunosuppression after cadaveric renal transplantation
61. Altered pharmacokinetics of cyclosporin in heart-lung transplant recipients with cystic fibrosis
62. Cyclosporine bioavailability in heart-lung transplant candidates with cystic fibrosis
63. Clinical use and bioavailability of tacrolimus in heart-lung and double lung transplant recipients with cystic fibrosis
64. Sandimmun neoral improves the bioavailability of cyclosporin A and decreases inter-individual variations in patients affected with cystic fibrosis
65. Improved absorption and bioavailability of cyclosporine A from a microemulsion formulation in lung transplant recipients affected with cystic fibrosis
66. Relative bioavailability of cyclosporin from conventional and microemulsion formulations in heart-lung transplant candidates with cystic fibrosis
67. An investigation of the pharmacokinetics, toxicity, and clinical efficacy of Neoral cyclosporin in cystic fibrosis patients
68. Immunosuppressive therapy, management, and outcome of heart transplant recipients during pregnancy
69. Immunosuppressive drugs in pregnancy
70. Cyclosporin requirement during pregnancy in renal transplant recipients
71. The outcome of pregnancy following renal transplantation - The experience of a single center
72. Pregnancy outcomes in female renal transplant recipients
73. Drug safety issues in pregnancy following transplantation and immunosuppression: Effects and outcomes